In this context, IL‐6 blockade by tocilizumab may be a therapeutic avenue.[70] Another study confirmed that CRS does not play an essential role in other typical conditions, and therefore doubts the high effectiveness of anticytokine therapies.[71] The immune system activation pattern was used to calculate a linear prognostic Dublin–Boston score based on the interleukin‐6 to the interleukin‐10 ratio for predicting outcomes in COVID‐19.[72]. The gene discussed is IL6; the disease is COVID-19.